News
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director Vinay Prasad reveal new COVID-19 vaccine strategy following Novavax approval;
Moscicki previously served as the deputy center director for science operations at the FDA’s Center for Drug Evaluation and ...
An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.
Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.
Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...
Pfizer has entered into an exclusive global licensing agreement with 3SBio to develop, manufacture, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF pathways. The therapy is ...
Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies, to the pipeline, following a major trial setback this ...
One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback